Your session is about to expire
← Back to Search
Chemotherapy
Chemotherapy + Stem Cell Transplant for Multiple Myeloma
Phase 2
Waitlist Available
Research Sponsored by Robert H. Lurie Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
No active hepatitis with hepatitis C
No progressive disease after standard induction therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well combination chemotherapy and peripheral stem cell transplantation work in treating patients with multiple myeloma.
Who is the study for?
This trial is for patients with any stage of multiple myeloma, who are physiologically under 65 years old and have good heart, liver, kidney, and lung function. They should not have active hepatitis C or a history of significant heart disease unless cleared by a cardiologist. HIV negative individuals with controlled bilirubin levels and no more than two prior chemotherapy treatments can join.Check my eligibility
What is being tested?
The study is testing the effectiveness of combining different chemotherapy drugs with peripheral stem cell transplantation to treat multiple myeloma. The goal is to see if higher doses of chemo drugs given in this way can kill more cancer cells in phase II of the trial.See study design
What are the potential side effects?
Chemotherapy may cause side effects like nausea, fatigue, hair loss, increased risk of infection due to low blood counts, mouth sores, and diarrhea. Stem cell transplantation carries risks such as graft-versus-host disease (immune reaction), infections due to weakened immune system post-transplantation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I do not have active hepatitis C.
Select...
My condition hasn't worsened after initial cancer treatment.
Select...
I have multiple myeloma at any stage.
Select...
My cancer does not produce detectable markers, but cancerous cells were found in my bone marrow or as isolated tumors.
Select...
My lung function is at least 60% of what is expected.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My bilirubin level is 2.0 mg/dL or lower.
Select...
My kidney function is good, with creatinine below 2.0 or clearance above 50 mL/min.
Select...
I have no symptoms of heart disease or have been cleared by a cardiologist.
Select...
My heart's pumping ability is at least 45%.
Select...
I am 65 or younger.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Robert H. Lurie Cancer CenterLead Sponsor
21 Previous Clinical Trials
1,797 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,153 Total Patients Enrolled
578 Trials studying Multiple Myeloma
188,730 Patients Enrolled for Multiple Myeloma
Jane N. Winter, MDStudy ChairRobert H. Lurie Cancer Center
9 Previous Clinical Trials
682 Total Patients Enrolled
1 Trials studying Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have active hepatitis C.My condition hasn't worsened after initial cancer treatment.I have multiple myeloma at any stage.My cancer does not produce detectable markers, but cancerous cells were found in my bone marrow or as isolated tumors.My lung function is at least 60% of what is expected.My cancer responded completely to the first round of chemotherapy.I am fully active or restricted in physically strenuous activity but can do light work.My blood cell levels are not specified for this trial.My bilirubin level is 2.0 mg/dL or lower.My kidney function is good, with creatinine below 2.0 or clearance above 50 mL/min.I have no symptoms of heart disease or have been cleared by a cardiologist.Not applicable.My heart's pumping ability is at least 45%.I am 65 or younger.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What safety measures have been taken to guarantee the security of those partaking in this therapy?
"The safety of this treatment was ranked at a 2; since it is only in the second stage of clinical trials, there are some data points that support its safety, but no evidence yet demonstrating efficacy."
Answered by AI
Are recruitment efforts still underway for this experiment?
"According to the clinicaltrials.gov website, enrolling for this particular trial has been discontinued since January 3rd 2014. Fortunately, there are 811 other medical trials actively recruiting patients at present."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger